SCHEDULE: Third Rock Ventures Cuts Tango Therapeutics Stake to 5.85%
Beneficial Ownership Update
Third Rock Ventures has significantly reduced its beneficial ownership in Tango Therapeutics, Inc., now holding approximately 5.85% of common stock.
Summary
- Third Rock Ventures IV, L.P. and its affiliates (Reporting Persons) filed an Amendment No. 3 to their Schedule 13D regarding Tango Therapeutics, Inc.
- The amendment reports a decrease of over one percent (1%) in the aggregate percentage ownership held by the Reporting Persons.
- As of November 19, 2025, the Reporting Persons beneficially own 7,874,574 shares of Tango Therapeutics' Common Stock.
- This represents approximately 5.85% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q.
- Between September 25, 2025, and November 19, 2025, TRV IV disposed of a total of 6,489,401 shares in open market transactions.
- The weighted average prices for these dispositions ranged from $8.00 to $10.15 per share.
Sentiment
Score: 3
Explanation: The sentiment is negative due to a significant reduction in ownership by a major institutional investor, which typically signals a lack of conviction or a strategic exit, potentially impacting investor confidence and stock price.
Negatives
- Third Rock Ventures, a significant early investor, has substantially reduced its stake in Tango Therapeutics by over 1% of the total outstanding shares.
- The sale of 6,489,401 shares by a major institutional investor could signal reduced confidence in the company's near-term prospects or a strategic portfolio rebalancing.
Risks
- Significant selling by a major institutional investor like Third Rock Ventures could put downward pressure on Tango Therapeutics' stock price.
- Reduced institutional ownership might decrease overall investor confidence and liquidity for the stock.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from Tango Therapeutics. The reporting person's actions reflect a reduction in their investment stake.
Industry Context
This filing reflects a significant portfolio adjustment by a venture capital firm, Third Rock Ventures, in one of its portfolio companies, Tango Therapeutics. While not directly indicative of broader industry trends, substantial divestments by early-stage investors can sometimes precede or coincide with shifts in sector-specific investment strategies or company-specific performance re-evaluations within the biotechnology sector.
Stakeholder Impact
- Shareholders: May experience decreased stock price due to selling pressure and potentially reduced investor confidence following a major institutional divestment.
- Employees: No direct impact mentioned, but significant investor exits can sometimes lead to broader concerns about company stability or future funding.
Key Dates
| Date | Description |
|---|---|
| 2025-09-25 | TRV IV disposed of 500,000 shares in the open market at a weighted average price of $8.02 per share. |
| 2025-10-23 | TRV IV disposed of 477,401 shares in the open market at a weighted average price of $10.15 per share. |
| 2025-10-28 | Date as of which 134,593,998 shares of common stock were issued and outstanding, as disclosed in the Issuer's 10-Q. |
| 2025-11-04 | Date the Issuer's 10-Q was filed with the Securities and Exchange Commission, disclosing shares outstanding. |
| 2025-11-06 | TRV IV disposed of 1,500,000 shares in the open market at a weighted average price of $8.00 per share. |
| 2025-11-10 | TRV IV disposed of 278,956 shares in the open market at a weighted average price of $8.00 per share. |
| 2025-11-11 | TRV IV disposed of 721,044 shares in the open market at a weighted average price of $8.20 per share. |
| 2025-11-12 | TRV IV disposed of 1,512,000 shares in the open market at a weighted average price of $8.20 per share. |
| 2025-11-14 | TRV IV disposed of 600,000 shares in the open market at a weighted average price of $8.20 per share. |
| 2025-11-17 | TRV IV disposed of 14,875 shares in the open market at a weighted average price of $8.27 per share. |
| 2025-11-19 | Date of event requiring the filing, and TRV IV disposed of 885,125 shares in the open market at a weighted average price of $8.26 per share. |
| 2025-11-21 | Date the Schedule 13D/A was signed by Kevin Gillis. |
Recommendation
sellThe significant reduction in stake by Third Rock Ventures, a prominent venture capital firm and early investor, suggests a loss of conviction or a strategic exit. Such a large divestment by an informed insider typically signals potential headwinds for the company or a belief that the stock has reached its peak for the investor's investment horizon. This action could lead to downward pressure on the stock price and reduced investor confidence, making a 'sell' recommendation prudent for investors holding the stock.
Keywords
Tango Therapeutics, Third Rock Ventures, Schedule 13D/A, Beneficial Ownership, Stock Sale, Institutional Investor, Biotechnology, SEC Filing, TNGX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.